<DOC>
	<DOCNO>NCT01698931</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare efficacy repaglinide glyburide placebo hepatic glucose metabolism subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Repaglinide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes HbA1c ( glycosylated haemoglobin A1c ) 7 % BMI ( body mass index ) 32 kg/m^2 FBG ( fast blood glucose ) wash period 130220 mg/dl Currently treat diet OHA ( oral hypoglycaemic agent ) Current systemic treatment concomitant medication Known suspect history drug alcohol dependence Any significant concomitant disease cerebrovascular symptomatic peripheral vascular disease , malignant , disease severe treat untreated hypertension Hepatic disease Cardiac problem Active proliferative retinopathy Known suspect allergy trial product relate product Women fertile age woman intention become pregnant Body Mass Index ( BMI ) 32 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>